Slide Experience a new healthcare solution

MyLab™40

MyLab™40: Compact Console Ultrasound Systems

Developed on the acclaimed MyLab™ platform, the MyLab™40 license-based modular architecture can be configured to meet the individual needs of its users in various applications. A wide selection of advanced technologies, in addition to a complete range of broadband transducers, makes the MyLab™40 a full-service system without compromise in image quality and ease-of-use.

Click the image to view Esaote Advanced Technologies Images

Imaging Processing: Esaote offers many technologies for imaging enhancement. With TEI™, the harmonic signal is fully preserved without degradation of acoustic information. MView and XView improve the quality of ultrasound images by reducing the presence of artifacts, shadowing and speckle.

CnTI™ – Contrast Tuned Imaging: Esaote’s revolutionary technology, in combination with latest generation ultrasound contrast agents, provides impressive clinical results due to precise micro-bubble detection. The very low applied acoustic pressure, allows the bubbles life time to be increased, for a clear identification of arterial and late phase. The very high probe sensitivity and low level of noise and artifacts bring precise diagnosis, both for lesions detection and characterization. A contrast-dedicated quantification tool is also available.

X4D/X3D: Esaote’s volumetric technology takes full advantage of the touch panel to optimize workflow, ease of use, and represents a breakthrough in technology.

Click the image to view Esaote Advanced Technologies Images

RFQIMT – Innovation and Accuracy in Vascular Imaging: the measurements that are based on beyond state of the art RF-data technology, are real-time, accurate and provide measurement quality indicators overlaid on the B-mode ultrasound image.
>> DOWNLOAD INTERACTIVE PDF BROCHURE [2.3 MB]

XStrain™: Strain-Strain Rate top analysis technique for myocardial function evaluation.
>> DOWNLOAD INTERACTIVE PDF BROCHURE [2.5 MB]

XHF: very High-Frequency capability

The use of contrast agents in the USA is limited by FDA to left ventricle opacification and visualization of the left ventricular endocardial border.
Windows® is a registered trademark of Microsoft Corporation.
Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries.
For further details, please contact your Esaote sales representative.